Syndax Pharmaceuticals Inc SNDX
News
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
Syndax Says Pulmonary Fibrosis Drug Trial Misses Primary Endpoint
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Syndax Wins FDA Approval for Leukemia Treatment


